In the present study we have assessed MED12 gene status in 33 uterine tumors including nine LM, five atypical LM, nine STUMP and ten LMS, and we show not only that 66.6% of LM present MED12 mutations, confirming previous results, but also that 11% of STUMP and 20% of uterine LMS present MED12 mutations. This evidence concerns the gene MED12 and lymphangioma.